{
    "clinical_study": {
        "@rank": "18473", 
        "arm_group": [
            {
                "arm_group_label": "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Ertugliflozin 5 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin 5 mg, oral, once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Ertugliflozin 15 mg", 
                "arm_group_type": "Experimental", 
                "description": "Ertugliflozin, oral, once daily for 52 weeks"
            }, 
            {
                "arm_group_label": "Sitagliptin 100 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Sitagliptin 100 mg, oral, once daily for 52 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin\n      given together or alone along with metformin in participants with type 2 diabetes mellitus\n      (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of\n      this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater\n      hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone."
        }, 
        "brief_title": "Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will include a 1-week screening period; an up to 12-week metformin titration/dose\n      stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase\n      A and (26-week Phase B) double-blind treatment period and a post-treatment telephone contact\n      14 days after the last dose of study medication."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 diabetes mellitus as per American Diabetes Association guidelines\n\n          -  On metformin monotherapy (>=1500 mg/day) for >=8 weeks with a Visit 1/Screening A1C\n             >=7.5% and <=11.0% (>=58 mmol/mol and <=97 mmol/mol) OR On metformin monotherapy\n             (>=1500 mg/day) for <8 weeks with a Visit 1/Screening A1C >=7.5% and <=11.0% (>=58\n             mmol/mol and <=97 mmol/mol) OR On metformin monotherapy <1500 mg/day with a Visit\n             1/Screening A1C >=8.0% and <=11.5% (>=64 mmol/mol and <=102 mmol/mol)\n\n          -  Body mass index (BMI) >=18.0 kg/m^2\n\n          -  Male or female not of reproductive potential\n\n          -  Female of reproductive potential who agrees to remain abstinent from heterosexual\n             activity or to use 2 acceptable combinations of contraception\n\n        Exclusion Criteria:\n\n          -  History of type 1 diabetes mellitus or ketoacidosis\n\n          -  History of other specific types of diabetes (e.g., genetic syndromes, secondary\n             pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and\n             post-organ transplant\n\n          -  A known hypersensitivity or intolerance to any sodium glucose co-transporter (SGLT2)\n             inhibitor or sitagliptin\n\n          -  Has been treated with any of the following agents within 12 weeks of study start or\n             during the pre-randomization period: Insulin of any type (except for short-term use\n             [i.e., <=7 days] during concomitant illness or other stress), other injectable\n             anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone\n             or rosiglitazone, other sodium glucose co-transporter 2 (SGLT2) inhibitors, alpha\n             glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4\n             inhibitor), sulfonylureas (SUs), bromocriptine (Cycloset\u2122), colesevelam (Welchol\u2122),\n             any other AHA with the exception of the protocol-approved agents\n\n          -  Is on a weight-loss program or weight-loss medication or other medication associated\n             with weight changes and is not weight stable prior to study start\n\n          -  Has undergone bariatric surgery within the past 12 months or >12 months and is not\n             weight stable prior to study start\n\n          -  A history of myocardial infarction, unstable angina, arterial revascularization,\n             stroke, transient ischemic attack, or New York Heart Association (NYHA) functional\n             class III-IV heart failure within 3 months of study start\n\n          -  Active, obstructive uropathy or indwelling urinary catheter\n\n          -  History of malignancy <=5 years prior to study start, except for adequately treated\n             basal cell or squamous cell skin cancer or in situ cervical cancer\n\n          -  A known history of human immunodeficiency virus (HIV)\n\n          -  A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a\n             clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative\n             or myelodysplastic syndromes, thrombocytopenia)\n\n          -  A medical history of active liver disease (other than non-alcoholic hepatic\n             steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or\n             symptomatic gallbladder disease\n\n          -  Any clinically significant malabsorption condition\n\n          -  Current treatment for hyperthyroidism\n\n          -  On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior\n             study start\n\n          -  On a previous clinical study with ertugliflozin\n\n          -  eGFR (using the 4-variable Modification of Diet in Renal Disease Study Equation\n             (MDRD) equation) <60 mL/min/1.73 m^2\n\n          -  Serum creatinine >= 1.3 mg/dL (115 \u00b5mol/L) for males and >= 1.2 mg/dL (106 \u00b5mol/L)\n             for females\n\n          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times upper\n             limit of normal\n\n          -  Hemoglobin <12 g/dL (120 g/L) for males and <11 g/dL (110 g/L) for females.\n\n          -  Participated in other studies involving investigational drug(s) 30 days prior to\n             study start\n\n          -  Surgical procedure within 6 weeks prior to study start or major surgery planned\n             during the trial\n\n          -  Positive urine pregnancy test\n\n          -  Pregnant or breast-feeding, or planning to conceive during the trial, including 14\n             days following the last dose of study medication\n\n          -  Planning to undergo hormonal therapy in preparation for egg donation during the\n             trial, including 14 days following the last dose of study medication\n\n          -  Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or\n             engages in binge drinking\n\n          -  Donated blood or blood products within 6 weeks of study start"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02099110", 
            "org_study_id": "8835-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sitagliptin 100 mg", 
                "description": "Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", 
                "intervention_name": "Matching Placebo to Ertugliflozin 5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 5 mg", 
                    "Sitagliptin 100 mg"
                ], 
                "description": "Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", 
                "intervention_name": "Matching Placebo to Ertugliflozin 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg", 
                    "Ertugliflozin 15 mg"
                ], 
                "description": "Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", 
                "intervention_name": "Matching Placebo to sitagliptin 100 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 5 mg", 
                    "Ertugliflozin 15 mg"
                ], 
                "description": "Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", 
                "intervention_name": "Ertugliflozin 5 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-8835", 
                    "PF-04971729"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 15 mg"
                ], 
                "description": "Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", 
                "intervention_name": "Ertugliflozin 10 mg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "MK-8835", 
                    "PF-04971729"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                    "Sitagliptin 100 mg"
                ], 
                "description": "Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period", 
                "intervention_name": "Sitagliptin 100 mg", 
                "intervention_type": "Drug", 
                "other_name": "JANUVIA\u00ae"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 5 mg", 
                    "Ertugliflozin 15 mg", 
                    "Sitagliptin 100 mg"
                ], 
                "description": "Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period", 
                "intervention_name": "Metformin >= 1500 mg/day", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Glucophage", 
                    "Glucophage XR"
                ]
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 5 mg", 
                    "Ertugliflozin 15 mg", 
                    "Sitagliptin 100 mg"
                ], 
                "description": "Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion", 
                "intervention_name": "Insulin Glargine Rescue Medication", 
                "intervention_type": "Biological", 
                "other_name": "Lantus"
            }, 
            {
                "arm_group_label": [
                    "Ertugliflozin 5 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 15 mg + sitagliptin 100 mg", 
                    "Ertugliflozin 5 mg", 
                    "Ertugliflozin 15 mg", 
                    "Sitagliptin 100 mg"
                ], 
                "description": "Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion", 
                "intervention_name": "Glimepiride Rescue Medication", 
                "intervention_type": "Drug", 
                "other_name": "AMARYL"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Glargine", 
                "Sitagliptin", 
                "Insulin", 
                "Metformin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fargo", 
                    "country": "United States", 
                    "state": "North Dakota", 
                    "zip": "58103"
                }, 
                "name": "Call for Information (Investigational Site 0078)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline in A1C", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Number of Participants Who Experience an Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 54 weeks"
            }, 
            {
                "measure": "Number of Participants Who Discontinue Study Medication due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02099110"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from Baseline in Body Weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Fasting Plasma Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Change from Baseline in Systolic Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }, 
            {
                "measure": "Percentage of Participants Achieving a Hemoglobin A1C of <7%", 
                "safety_issue": "No", 
                "time_frame": "Week 26"
            }, 
            {
                "measure": "Change from Baseline in Parameters of Beta-cell Function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 26"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}